Pharmacogenomics Results Affect Patients' Plan of Care & Changes in

Clinical Trial Description

The general design of this study is collecting data and reviewing Principal Investigators' Standard Operating Procedures on Pharmacogenomic testing and changes made to their specific SOP. ;

Study Design

Related Conditions & MeSH terms

Pharmacogenomic

See also
	Status	Clinical Trial	Phase
	Recruiting	`NCT03128463` - Pharmacogenomic Study on Anti-VEGF Medicine in Treatment of Macular Neovascular Diseases	N/A
	Completed	`NCT05036421` - Effect of Glucuronosyltransferase (UGT) Genetic Variation on Pharmacokinetics of Empagliflozin	Phase 3

See also

Status

Clinical Trial

Phase

Recruiting

NCT03128463 - Pharmacogenomic Study on Anti-VEGF Medicine in Treatment of Macular Neovascular Diseases

N/A

Completed

NCT05036421 - Effect of Glucuronosyltransferase (UGT) Genetic Variation on Pharmacokinetics of Empagliflozin

Phase 3

Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.

Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.

Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

NCT number	NCT03322189
Study type	Observational
Source	Data Collection Analysis Business Management
Contact
Status	Enrolling by invitation
Phase
Start date	March 22, 2017
Completion date	April 1, 2020

Pharmacogenomics Results Affect Patients' Plan of Care and Changes in Medication Prescription(s)

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms